2026-04-29T04:09:42Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/229712024-11-29T00:44:28Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Martínez-López, Icíar
author
Maurino, Jorge
author
Sanmartin-Fenollera, Patricia
author
Ontanon-Nasarre, Ana
author
Santiago-Perez, Alejandro
author
Moya-Carmona, Isabel
author
Gustavo Garcia-Collado, Carlos
author
Fernandez-Del Olmo, Raquel
author
Garcia-Arcelay, Elena
author
Sarmiento, Monica
author
Carreno, Agata
author
Perez-Encinas, Montserrat
2024-09-13T09:14:44Z
2024-09-13T09:14:44Z
2020-06
Martínez López I, Maurino J, Sanmartin-Fenollera P, Ontanon-Nasarre A, Santiago-Perez A, Moya-Carmona I, et al. Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis. Pharmacy. 2020 Jun;8(2):61.
http://hdl.handle.net/20.500.13003/10487
https://hdl.handle.net/20.500.12105/22971
32272683
10.3390/pharmacy8020061
2226-4787
Pharmacy
552756500049
L632084844
Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists ' preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 +/- 7.8 years, 63.1% female, mean years of professional experience: 16.1 +/- 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS.
eng
Multiple sclerosis
Pharmacist
Preferences
Disease-modifying therapy
Disease progression
Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
research article